| Name | Title | Contact Details |
|---|---|---|
Laura Krzastek |
Executive Director, Compliance | Profile |
Christina Ackermann |
Executive Vice President, Chief Legal Officer and General Counsel | Profile |
Jonathon Kellerman |
Chief Compliance Officer | Profile |
Robert Bailey |
General counsel | Profile |
Robert Bailey |
Executive Vice President and Chief Legal Officer | Profile |
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
Emisphere Technologies, Inc. is a Cedar Knolls, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cognition Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Berkeley Premium Nutraceuticals currently offers six supplements to address issues including sexual health, fatigue, night vision, and cardiovascular health. The Company is also investigating new formulas to assist with other concerns, including prostate